<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159939" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Levodopa/Carbidopa/Entacapone Combination Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muranova</surname>
            <given-names>Alexandra</given-names>
          </name>
          <aff>University of South Alabama</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shanina</surname>
            <given-names>Elena</given-names>
          </name>
          <aff>University of Texas Medical Branch</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexandra Muranova declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elena Shanina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>12</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159939.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Levodopa/carbidopa/entacapone (LCE) is a combination therapy to address&#x000a0;Parkinson disease&#x000a0;in patients exhibiting symptoms of motor fluctuations and signs of wearing off while on levodopa/carbidopa.<xref ref-type="bibr" rid="article-159939.r1">[1]</xref>&#x000a0;Parkinson disease is the second most common neurodegenerative disorder worldwide. LCE was approved by the U.S. Food and Drug Administration (FDA) in June 2003.<xref ref-type="bibr" rid="article-159939.r2">[2]</xref>&#x000a0;</p>
        <p>The degeneration of the nigrostriatal system in patients with Parkinson disease leads to a diminished synthesis of the neurotransmitter dopamine. LCE&#x000a0;falls under the category of dopamine replacement therapy and&#x000a0;comprises 3&#x000a0;commonly used ingredients for Parkinson disease&#x02014;a dopamine precursor (levodopa), an aromatic <italic toggle="yes">L</italic>-amino acid decarboxylase (AADC) inhibitor (carbidopa), and a catechol-O-methyltransferase (COMT) inhibitor (entacapone).&#x000a0;This triple combination treatment enables enhanced and more consistent bioavailability of levodopa in the brain, leading to improved on-time or symptom-free periods for patients.&#x000a0;</p>
        <p>Although the combination of levodopa and carbidopa has been a fundamental aspect of Parkinson disease treatment for decades, the addition of entacapone serves to slow down the degradation of levodopa in peripheral tissues. This results in an elevated plasma concentration and enhanced transfer of the levodopa substrate to the central nervous system (CNS).<xref ref-type="bibr" rid="article-159939.r3">[3]</xref> The triple combination of agents enhances convenience and compliance by enabling patients to take a single pill instead of administering levodopa/carbidopa and entacapone separately. LCE is typically prescribed for patients facing end-dose motor fluctuations and the "wearing-off phenomenon" on the levodopa/carbidopa dual agent.<xref ref-type="bibr" rid="article-159939.r4">[4]</xref>&#x000a0;</p>
        <p><bold>FDA-Approved Indications</bold>&#x000a0;</p>
        <p>LCE is indicated for the treatment of motor fluctuations in adult patients with Parkinson disease in the following 2 scenarios:</p>
        <list list-type="bullet">
          <list-item>
            <p>As a single agent with equivalent strength of its 3 components, intended for patients who currently use these individual products separately.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As a replacement treatment for levodopa/carbidopa when patients experience a "wearing-off phenomenon" on a daily levodopa dose of 600 mg or less without experiencing dyskinesia.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Reports indicate that the use of LCE for restless leg syndrome (RLS) offers prolonged symptom control throughout the night.<xref ref-type="bibr" rid="article-159939.r5">[5]</xref> However, the preference for dopamine replacement therapy is limited in RLS due to the potential for dopaminergic augmentation.</p>
      </sec>
      <sec id="article-159939.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Levodopa/Carbidopa&#x000a0;</bold>
</p>
        <p>Levodopa, or <italic toggle="yes">L</italic>-Dopa, is a dopamine precursor in the central and peripheral nervous systems. Carbidopa is a peripheral AADC inhibitor that reduces levodopa metabolism. The historical efficacy of the levodopa/carbidopa combination makes it the most effective symptomatic therapy for Parkinson disease. In Parkinson disease, the progressive degeneration of dopaminergic nigrostriatal neurons gives rise to cardinal motor symptoms such as bradykinesia, rigidity, and tremor. Upon conversion to dopamine in the CNS, <italic toggle="yes">L</italic>-Dopa compensates for the lost neurotransmitter, thereby improving symptoms associated with Parkinson disease.&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Approximately 70% of orally administered levodopa is absorbed in the small intestine, where it undergoes metabolism to dopamine by AADC. However, only 1% of levodopa crosses the blood-brain barrier (BBB) to exert its therapeutic effect by enhancing dopaminergic activity in presynaptic neuron terminals.<xref ref-type="bibr" rid="article-159939.r3">[3]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;Approximately 20% to 30% of levodopa and 36% of carbidopa bind to plasma proteins. Although carbidopa does not cross the BBB, it facilitates the entry of levodopa into the CNS. This enables the administration of a considerably lower levodopa dose while extending its half-life to 90 minutes.<xref ref-type="bibr" rid="article-159939.r6">[6]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;The&#x000a0;average half-life of levodopa/carbidopa is 1.5 hours. Levodopa undergoes primary metabolism through decarboxylation. In cases where this pathway is unavailable, an alternative pathway involving methylation with COMT becomes more prominent in its metabolism.</p>
        <p><bold>Elimination:</bold> Metabolites of both drugs are excreted with urine.</p>
        <p><bold>Entacapone</bold>&#x000a0;</p>
        <p>Entacapone is a selective COMT inhibitor that prevents the degradation of levodopa in peripheral tissues, enhancing its effects by extending the half-life by up to 75% and increasing the maximum plasma concentration.<xref ref-type="bibr" rid="article-159939.r7">[7]</xref>&#x000a0;Therefore, more levodopa reaches the CNS over an extended period, ensuring a more consistent availability of dopamine. Importantly, it has minimal impact on the metabolism of other catecholamines, including epinephrine and norepinephrine.&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Entacapone is rapidly absorbed through the intestinal mucosa and reaches peak concentration (Cmax) in the plasma within 0.5 to 0.7 hours.&#x000a0;</p>
        <p><bold>Distribution:</bold>&#x000a0;Entacapone exhibits a high plasma protein binding capacity, with 98% of the active substance bound to albumin.<xref ref-type="bibr" rid="article-159939.r8">[8]</xref>&#x000a0;</p>
        <p><bold>Metabolism:</bold>&#x000a0;Entacapone has an average half-life of 1 hour, and the liver predominantly metabolizes the medication through glucuronidation before its elimination via the biliary tract.<xref ref-type="bibr" rid="article-159939.r9">[9]</xref>&#x000a0;</p>
        <p><bold>Elimination:</bold> Only 0.2 % of non-metabolized substance is excreted in the urine.<xref ref-type="bibr" rid="article-159939.r7">[7]</xref></p>
      </sec>
      <sec id="article-159939.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Form and&#x000a0;Strengths</bold>
</p>
        <p>LCE is available only in tablet form for oral administration, and these tablets should not be crushed or chewed. The optimal daily dosage is determined on an individual basis for each patient.</p>
        <p>Currently, 6 distinct tablet strengths are commercially available, as listed below, featuring a 1:4 ratio of standard-release levodopa/carbidopa and 200 mg of entacapone. Each tablet encompasses a levodopa dose ranging from 50 to 200 mg and a carbidopa dose ranging from 12.5 to 50 mg, respectively.<xref ref-type="bibr" rid="article-159939.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>12.5 mg of carbidopa, 50 mg of levodopa, and 200 mg of entacapone</p>
          </list-item>
          <list-item>
            <p>18.75 mg of carbidopa, 75 mg of levodopa, and 200 mg of entacapone</p>
          </list-item>
          <list-item>
            <p>25 mg of carbidopa, 100 mg of levodopa, and 200 mg of entacapone</p>
          </list-item>
          <list-item>
            <p>31.25 mg of carbidopa, 125 mg of levodopa, and 200 mg of entacapone</p>
          </list-item>
          <list-item>
            <p>37.5 mg of carbidopa, 150 mg of levodopa, and 200 mg of entacapone</p>
          </list-item>
          <list-item>
            <p>50 mg of carbidopa, 200 mg of levodopa, and 200 mg of entacapone</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Healthcare providers&#x000a0;recommend not taking more than 1600 mg of entacapone in 24 hours due to potential clinical adverse effects. In addition, to mitigate the risk of entacapone overdose, it is not recommended to administer multiple tablets of LCE simultaneously. Patients maintaining stable doses of levodopa/carbidopa with supplementary entacapone can transition to the appropriate combination pill's corresponding strength without requiring any adjustments.<xref ref-type="bibr" rid="article-159939.r10">[10]</xref>&#x000a0;There are no specific guidelines for transitioning patients either from extended-release levodopa/carbidopa or those not on a levodopa/carbidopa formulation combined in a 1:4 ratio to LCE. However, it is advisable to refrain from administering LCE concurrently with protein-rich foods to prevent diminished intestinal absorption, delayed gastric emptying, and competition for amino acid transport across the BBB.<xref ref-type="bibr" rid="article-159939.r11">[11]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Limited data are available on the use of levodopa/carbidopa in individuals with hepatic impairment. Caution is recommended, especially in cases of severe liver failure, with periodic monitoring of hepatic function. When administered as a standalone medication, entacapone's pharmacokinetics are notably influenced by liver impairment and biliary obstruction. Therefore, particular caution is advised when initiating LCE therapy in patients with hepato-biliary disease.&#x000a0;</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The pharmacokinetics of entacapone remain unaffected by renal impairment, and there are no specific studies examining the impact of kidney disease on combination therapy. However, caution is generally recommended when administering LCE to patients with severe renal impairment.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;As&#x000a0;the incidence of Parkinson disease in pregnant patients is rare, insufficient data exist to ascertain the safety of LCE in this population.<xref ref-type="bibr" rid="article-159939.r12">[12]</xref>&#x000a0;LCE is considered an FDA pregnancy category C drug due to evidence of birth malformations in animal models.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Research indicates that a minimal quantity of levodopa can be excreted in breast milk. Levodopa has the potential to suppress lactation by reducing serum prolactin levels. However, no studies assess levodopa's long-term effects on breastfed infants.&#x000a0;</p>
        <p><bold>Pediatric population:&#x000a0;</bold>The guidelines for using LCE in the pediatric population have not been&#x000a0;established, and the medication is not prescribed for patients younger&#x000a0;than 18.<xref ref-type="bibr" rid="article-159939.r13">[13]</xref></p>
        <p><bold>Older population:</bold> No dosage adjustment is necessary for the older population, as there is no difference in peak concentrations between younger and older patients after a single-dose administration of LCE.</p>
      </sec>
      <sec id="article-159939.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse reactions are typically linked to levodopa, carbidopa, and entacapone individually, often exhibiting a dose-dependent pattern. Most of the reported adverse effects associated with LCE are mild or moderate, with drug discontinuation occurring in only 1% to 4% of cases.<xref ref-type="bibr" rid="article-159939.r14">[14]</xref>&#x000a0;The risk of CNS adverse effects is more common with LCE than with levodopa or levodopa/carbidopa alone. LCE is associated with worsening dyskinesias, which typically manifest earlier than with levodopa/carbidopa alone but often improve with a reduction in levodopa/carbidopa dosage. Generally, wearing-off symptoms do not significantly differ between patients treated with levodopa/carbidopa and those treated with LCE.<xref ref-type="bibr" rid="article-159939.r15">[15]</xref>&#x000a0;</p>
        <p>Nausea and vomiting are common adverse effects, often arising as a result of peripheral dopamine effects, and tend to diminish with concurrent use of carbidopa.<xref ref-type="bibr" rid="article-159939.r16">[16]</xref> Diarrhea is more prevalent with LCE use and may affect up to 10% of treated patients. If persistent, it could be associated with underlying drug-induced microscopic lymphocytic colitis, potentially necessitating discontinuation of the medication. In addition, episodes of orthostatic hypotension and syncope have been reported. Adverse events associated with elevated dopamine levels reaching the CNS include hallucinations, impulse control disorders, depression, and heightened suicidal tendencies.<xref ref-type="bibr" rid="article-159939.r9">[9]</xref> Caution should be exercised in treating patients with a history or an increased risk of psychosis. As LCE use has been linked to sleep attacks and increased somnolence, discontinuation of the drug may be necessary if these effects significantly impede daily activities.<xref ref-type="bibr" rid="article-159939.r17">[17]</xref>&#x000a0;</p>
        <p>Treatment with LCE may elevate the risk of upper gastrointestinal tract bleeding in individuals with a history of ulcers. Reports suggest a slightly increased risk of prostate cancer and cardiovascular events.<xref ref-type="bibr" rid="article-159939.r18">[18]</xref>&#x000a0;Rhabdomyolysis and manifestations resembling neuroleptic malignant syndrome (NMS) have been reported in patients who were rapidly discontinued from LCE without a gradual weaning-off process.<xref ref-type="bibr" rid="article-159939.r19">[19]</xref>&#x000a0;Notably, it is recommended to be cautious when discontinuing LCE therapy, and patients should be closely monitored. NMS is considered a medical emergency and should be suspected in patients displaying symptoms, including muscle rigidity, confusion, hyperthermia, and associated autonomic dysfunction such as tachycardia, tachypnea, and blood pressure fluctuations. A common adverse effect of using entacapone is a benign urine discoloration that appears dark reddish or orange due to the presence of its metabolites in the urine.<xref ref-type="bibr" rid="article-159939.r20">[20]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Caution should be exercised when administrating LCE concomitantly with dopamine D2 receptor antagonists, tricyclic antidepressants, antihypertensive medications, phenytoin, papaverine, iron salts, metoclopramide, and other drugs interfering with biliary excretion such as cholestyramine, probenecid, rifampicin, erythromycin, ampicillin, and chloramphenicol.</p>
      </sec>
      <sec id="article-159939.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the FDA-approved label, LCE is contraindicated in patients receiving nonselective monoamine oxidase (MAO) inhibitors such as tranylcypromine, phenelzine, and isocarboxazid. These medications should be discontinued at least 14 days&#x000a0;before&#x000a0;initiating LCE therapy. Furthermore, LCE is contraindicated in individuals with a history of narrow-angle glaucoma.<xref ref-type="bibr" rid="article-159939.r21">[21]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>LCE should not be prescribed for patients with a history of melanoma or suspicious skin lesions.<xref ref-type="bibr" rid="article-159939.r21">[21]</xref> Extra caution is warranted when prescribing LCE for patients with open-angle glaucoma. Additional monitoring is advisable when coadministering other medications metabolized by COMT, such as epinephrine, norepinephrine, apomorphine, dopamine, and dobutamine, to patients undergoing entacapone treatment. This combination therapy may result in tachycardia, tachyarrhythmias, and increased blood pressure. As hepatic metabolism is a significant route of medication excretion, extra caution is warranted when administering the medication to patients with a history of liver disease or biliary obstruction. Additional precautions include monitoring for syncope, colitis, and suicidal tendencies.<xref ref-type="bibr" rid="article-159939.r22">[22]</xref></p>
      </sec>
      <sec id="article-159939.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Formal monitoring is not explicitly mandated for patients undergoing LCE therapy. Nevertheless, individuals with a history of myocardial infarction complicated by atrial, nodal, or ventricular arrhythmias should undergo regular cardiac function tests during the initial LCE titration period. Similarly, patients with a history of wide-angle glaucoma should receive periodic intraocular pressure evaluations. Generally, regular monitoring of liver and kidney functions, along with cardiovascular status, is advisable for patients undergoing prolonged therapy with LCE. Furthermore, periodic screening for dyskinesias and CNS adverse effects, including confusion, hallucinations, and impulse control issues, is recommended.<xref ref-type="bibr" rid="article-159939.r23">[23]</xref></p>
      </sec>
      <sec id="article-159939.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>The literature describes only a limited number of cases of LCE toxicity, primarily attributed to dopamine overstimulation. Typical manifestations include altered mental status, hallucinations, other psychiatric symptoms, and cardiovascular disturbances such as tachycardia and hypotension.<xref ref-type="bibr" rid="article-159939.r24">[24]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>In case of suspected overdose, hospitalization is recommended. Rapid initiation of supportive measures, such as oral charcoal and gastric lavage, is necessary to eliminate unabsorbed products from the gastrointestinal tract. Currently, no specific antidote is available for LCE toxicity. When an overdose is suspected, it is advisable to monitor cardiovascular, respiratory, and renal function in a hospital setting.&#x000a0;Notably, due to entacapone's high protein binding capacity, hemodialysis is not effective in cases of LCE overdose.</p>
      </sec>
      <sec id="article-159939.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the complex and progressive nature of the condition, treating patients with Parkinson disease necessitates a multidisciplinary healthcare approach.<xref ref-type="bibr" rid="article-159939.r25">[25]</xref>&#x000a0;Often, patients are initially started on levodopa/carbidopa by their primary care providers. Early identification of the condition and treatment of&#x000a0;patients who need additional therapeutic interventions to address inadequate clinical response, adverse effects, and complications of long-term levodopa/carbidopa therapy is critical for improving care. Therefore, clinical scenarios wherein patients would benefit from transitioning to LCE therapy can enhance compliance, reduce the risk of immediate and long-term complications, and improve the overall quality of life for individuals with Parkinson disease. Comprehensive education for all healthcare team members regarding potential adverse effects, contraindications, and appropriate monitoring for LCE therapy is essential to achieve optimal outcomes and prevent morbidity associated with Parkinson disease and its complications.&#x000a0;</p>
        <p>As per the American Academy of Neurology (AAN) guidelines,&#x000a0;LCE can be beneficial for patients experiencing the end-of-dose wearing-off phenomenon.<xref ref-type="bibr" rid="article-159939.r26">[26]</xref> Consultation with neurologists and movement disorder specialists is crucial in the comprehensive management of Parkinson disease. These professionals conduct thorough assessments, considering symptoms and disease progression, to formulate personalized treatment plans. Neurologists play a pivotal role in monitoring motor fluctuations, adjusting pharmacotherapy, and staying abreast of research advancements to ensure optimal care for individuals with Parkinson disease.</p>
        <p>Pharmacists are critical in performing medication reconciliation and educating patients regarding adverse drug reactions. Nurses contribute by monitoring overall progress to improve compliance. Each member of the interprofessional healthcare team is essential, bringing their unique expertise to deliver comprehensive and effective patient care. Therefore, fostering effective interprofessional communication and care coordination among primary care providers, neurologists, pharmacists, and nurses&#x000a0;is&#x000a0;crucial. This collaborative approach is essential for enhancing patient safety, minimizing potential errors and delays, and ultimately contributing to improved outcomes for individuals affected by Parkinson disease.</p>
      </sec>
      <sec id="article-159939.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159939&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159939">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159939/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159939">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159939.s10">
        <title>References</title>
        <ref id="article-159939.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Levodopa/carbidopa/entacapone (Stalevo).</article-title>
            <source>Neurology</source>
            <year>2004</year>
            <month>Jan</month>
            <day>13</day>
            <volume>62</volume>
            <issue>1 Suppl 1</issue>
            <fpage>S64</fpage>
            <page-range>S64-71</page-range>
            <pub-id pub-id-type="pmid">14718682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Entacapone/levodopa/carbidopa combination tablet: Stalevo.</article-title>
            <source>Drugs R D</source>
            <year>2003</year>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>310</fpage>
            <page-range>310-1</page-range>
            <pub-id pub-id-type="pmid">12952501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jenner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Stalevo<sup>&#x000ae;</sup> : A pioneering treatment for OFF periods in Parkinsons disease.</article-title>
            <source>Eur J Neurol</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>30 Suppl 2</volume>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">37500177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeMaagd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>747</fpage>
            <page-range>747-73</page-range>
            <pub-id pub-id-type="pmid">26609209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yl&#x000e4;-Sahra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirvonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karvinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vahteristo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ellm&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2007</year>
            <season>Nov-Dec</season>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>335</fpage>
            <page-range>335-44</page-range>
            <pub-id pub-id-type="pmid">18090458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poulopoulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.</article-title>
            <source>Core Evid</source>
            <year>2010</year>
            <month>Jul</month>
            <day>27</day>
            <volume>5</volume>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">20694135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seeberger</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Levodopa/carbidopa/entacapone in Parkinson's disease.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>929</fpage>
            <page-range>929-40</page-range>
            <pub-id pub-id-type="pmid">19589043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habet</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2022</year>
            <month>Aug</month>
            <day>04</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>567</fpage>
            <page-range>567-575</page-range>
            <pub-id pub-id-type="pmid">35302623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Entacapone. A review of its use in Parkinson's disease.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>159</fpage>
            <page-range>159-77</page-range>
            <pub-id pub-id-type="pmid">10439935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reichmann</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Real-world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo<sup>&#x000ae;</sup> ) in Parkinson's disease.</article-title>
            <source>Eur J Neurol</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>30 Suppl 2</volume>
            <fpage>15</fpage>
            <page-range>15-20</page-range>
            <pub-id pub-id-type="pmid">37489705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Klingelhoefer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Longardner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Campagnolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levent</surname>
                <given-names>H&#x000c7;</given-names>
              </name>
              <name>
                <surname>Aureli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Metta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhidayasiri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chung-Faye</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Falup-Pecurariu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stocchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jenner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Warnecke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ray Chaudhuri</surname>
                <given-names>K</given-names>
              </name>
              <collab>International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group</collab>
            </person-group>
            <article-title>Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.</article-title>
            <source>Eur J Neurol</source>
            <year>2023</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>1465</fpage>
            <page-range>1465-1480</page-range>
            <pub-id pub-id-type="pmid">36757008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>T&#x000fc;fek&#x000e7;io&#x0011f;lu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hana&#x0011f;as&#x00131;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yal&#x000e7;&#x00131;n &#x000c7;akmakl&#x00131;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elibol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Esmeli Toku&#x000e7;o&#x0011f;lu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>ZE</given-names>
              </name>
              <name>
                <surname>Ertan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d6;zekmek&#x000e7;i</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Use of anti-Parkinson medication during pregnancy: a case series.</article-title>
            <source>J Neurol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>265</volume>
            <issue>8</issue>
            <fpage>1922</fpage>
            <page-range>1922-1929</page-range>
            <pub-id pub-id-type="pmid">29926223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thulin</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Nutt</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Levodopa in human breast milk: clinical implications.</article-title>
            <source>Neurology</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1920</fpage>
            <page-range>1920-1</page-range>
            <pub-id pub-id-type="pmid">9633767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reichmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-31</page-range>
            <pub-id pub-id-type="pmid">22288667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yi</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>709</fpage>
            <page-range>709-719</page-range>
            <pub-id pub-id-type="pmid">29713179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shuai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.</article-title>
            <source>Neurol Sci</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>2045</fpage>
            <page-range>2045-2054</page-range>
            <pub-id pub-id-type="pmid">32162166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trenkwalder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuoppam&#x000e4;ki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vahteristo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ellm&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Mar</month>
            <day>26</day>
            <volume>92</volume>
            <issue>13</issue>
            <fpage>e1487</fpage>
            <page-range>e1487-e1496</page-range>
            <pub-id pub-id-type="pmid">30824559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshammari</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>AlMutairi</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database.</article-title>
            <source>Saudi Pharm J</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-32</page-range>
            <pub-id pub-id-type="pmid">25685040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manjunath</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vikram</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant-like syndrome causing thrombocytopaenia: a rare association.</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <day>03</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30567175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaakkola</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>1233</fpage>
            <page-range>1233-50</page-range>
            <pub-id pub-id-type="pmid">10882160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeMaagd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>590</fpage>
            <page-range>590-600</page-range>
            <pub-id pub-id-type="pmid">26417179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepard</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Perepezko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Broen</surname>
                <given-names>MPG</given-names>
              </name>
              <name>
                <surname>Hinkle</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Butala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Nanavati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Nestadt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pontone</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Suicide in Parkinson's disease.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>822</fpage>
            <page-range>822-829</page-range>
            <pub-id pub-id-type="pmid">30661029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regensburger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ip</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kohl</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Schrader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jost</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>847</fpage>
            <page-range>847-861</page-range>
            <pub-id pub-id-type="pmid">36964457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sporer</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Carbidopa-levodopa overdose.</article-title>
            <source>Am J Emerg Med</source>
            <year>1991</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-8</page-range>
            <pub-id pub-id-type="pmid">1985650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Happe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huchtemann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000f6;nig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ohms</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwalbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Warnecke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Erzkamp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Enhancing medication therapy in Parkinson's disease by establishing an interprofessional network including pharmacists.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>441</fpage>
            <page-range>441-448</page-range>
            <pub-id pub-id-type="pmid">33893597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159939.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>de Bie</surname>
                <given-names>RMA</given-names>
              </name>
              <name>
                <surname>Roze</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miyasaki</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Espay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Martello</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gurwell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fitts</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cothros</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rafferty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagerbrant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Silsbee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <collab>Guideline Subcommittee of the AAN</collab>
            </person-group>
            <article-title>Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.</article-title>
            <source>Neurology</source>
            <year>2021</year>
            <month>Nov</month>
            <day>16</day>
            <volume>97</volume>
            <issue>20</issue>
            <fpage>942</fpage>
            <page-range>942-957</page-range>
            <pub-id pub-id-type="pmid">34782410</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
